Kieć-Wilk Beata, Guijt Paul, Dan Michaela, Abdelwahab Magy, Revel-Vilk Shoshana, Serratrice Christine
Unit of Rare Metabolic Diseases, Department of Pathophysiology, Jagiellonian University Medical College, 31-121 Krakow, Poland.
Metabolic Disease Clinic, The St. John Paul II Specialist Hospital, 31-202 Krakow, Poland.
J Clin Med. 2025 Jan 27;14(3):842. doi: 10.3390/jcm14030842.
Since the early 1990s, Gaucher Disease has been a pioneering condition for home-based enzyme replacement therapy (ERT), marking a significant shift in patient care. Since then, many countries have adopted this approach. However, home ERT is not possible in all countries. The aim of this article is to explore the implementation of home ERT for Gaucher disease, focusing on patient expectations, safety, compliance, economic benefits, and practical considerations. The PRISMA reporting protocol was followed, focusing on articles about home ERT for Gaucher Disease. Twenty articles were analyzed in the review, revealing promising outcomes. Home ERT has consistently been shown to be safe, to improve patients' quality of life, to reduce the utilization of hospital resources, and to pose no compliance issues. We believe it is essential to expand the availability of home ERT for Gaucher Disease to all countries where ERT is accessible. Based on the literature review, we present the conditions that must be met before starting home ERT programs.
自20世纪90年代初以来,戈谢病一直是家庭酶替代疗法(ERT)的先驱病症,标志着患者护理方面的重大转变。从那时起,许多国家都采用了这种方法。然而,并非所有国家都能开展家庭ERT。本文旨在探讨戈谢病家庭ERT的实施情况,重点关注患者期望、安全性、依从性、经济效益和实际考虑因素。遵循PRISMA报告协议,重点关注关于戈谢病家庭ERT的文章。在综述中分析了20篇文章,结果令人鼓舞。家庭ERT一直被证明是安全的,可改善患者生活质量,减少医院资源的使用,且不存在依从性问题。我们认为,有必要将戈谢病家庭ERT推广到所有可获得ERT的国家。基于文献综述,我们提出了启动家庭ERT项目之前必须满足的条件。